Oak Point Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Oak Point Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$4K	Buy	+240	New	+$4.69K	﹤0.01%	183

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oak Point Wealth Management's TEVA Position: Q1 2018 in Review

Oak Point Wealth Management opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2018: 240 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #183 among its holdings.

507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

Oak Point Wealth Management held 240 shares of Teva Pharmaceuticals worth $4K as of Q1 2018.
Teva Pharmaceuticals was a new Oak Point Wealth Management position in Q1 2018.
Teva Pharmaceuticals made up ﹤0.01% of Oak Point Wealth Management's portfolio in Q1 2018, its #183 holding.
507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Oak Point Wealth Management's 13F filing for Q1 2018, filed 30 Apr 2018.